Aethlon medical announces contract with namsa to advance hemopurifier clinical programs in cancer

San diego , jan. 30, 2023 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with namsa, a world leading medtech contract research organization (cro) offering global end-to-end development services to oversee the company's clinical trials investigating the hemopurifier, aethlon's immunotherapeutic device , for oncology indications. pursuant to the agreement, namsa will manage aethlon's study of the hemopurifier for patients in the united states and australia with various types of cancer tumors.
AEMD Ratings Summary
AEMD Quant Ranking